Advertisement

Hematopoiesis in HIV Infection: Use of Colony Stimulating Factors and Cytokines

  • Elaine Sloand
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 104)

Abstract

HIV infection is frequently accompanied by defects in hematopoiesis, particularly in those who have advanced HIV disease. There are multiple potential causes, including disorders that occur secondary to the HIV infection (e.g., infection, bone marrow infiltration by lymphoma), its treatment (e.g., sulfa, zidovudine), or primary infection of hematopoietic cells or stromal cells. Even those HIV-infected patients who have apparently normal hematopoiesis and normal blood counts are more prone to the myelosuppressive effects of cytotoxic therapy or other hematosuppressive medications. This chapter will discuss the potential causes of abnormal hematopoiesis that occurs in HIV infection, and the role of colony stimulating factors (CSFs) and cytokines in their management.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Bone Marrow Infiltration Oral Ganciclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989;261:3104–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheong I, Flegg PJ, Brettle RP, Welsby PD, Burns SM, Dhillon B, Leen CL, Gray JA. Cytomegalovirus disease in AIDS: the Edinburgh experience. Int J STD AIDS 1992;3:324–328PubMedGoogle Scholar
  3. 3.
    Snoeck R, Lagneaux L, Delforge A et al. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. Eur J Clin Microbiol Infect Dis 1990;9:615–619PubMedCrossRefGoogle Scholar
  4. 4.
    Kravcik S, Toye BW, Fyke K et al. Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population. J Acquir Immune Defic Syndr Hum Retroviral 1996;13:27–32CrossRefGoogle Scholar
  5. 5.
    Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5:36–46PubMedGoogle Scholar
  6. 6.
    Koch MA, Volberding PA, Lagakos SW et al. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med 1992;152:2286–2292PubMedCrossRefGoogle Scholar
  7. 7.
    Schacter LP, Rozencweig M, Beltangady M, et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency disease. Blood 1992: 80: 2968–2976Google Scholar
  8. 8.
    Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995;9:176–182PubMedCrossRefGoogle Scholar
  9. 9.
    Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis 1996;15:10–29PubMedCrossRefGoogle Scholar
  10. 10.
    Abkowitz JL, Brown KE, Wood RW, Kovach NL, Green SW, Young NS Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997; 176: 269–273PubMedCrossRefGoogle Scholar
  11. 11.
    Naides SJ, Howard EJ, Swack NS et al. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993;168:101–105PubMedCrossRefGoogle Scholar
  12. 12.
    Frickhofen N, Abkowitz JL, Safford M et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926–933PubMedGoogle Scholar
  13. 13.
    Fuller A, Moaven L, Spelman D, Spicer WJ, Wraith H, Curtis D, Leydon J, Doultree J, Locarnini S. Parvovirus B19 in HIV infection: A treatable cause of anemia. Pathology 1996; 28:277–280PubMedCrossRefGoogle Scholar
  14. 14.
    Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 1994;123:415–420PubMedGoogle Scholar
  15. 15.
    Karpatkin S, Nardi MA, Hymes KB. Immunologic thrombocytopenic purpura after heterosexual transmission of human immunodeficiency virus (HIV). Ann Intern Med 1988;109:190–193PubMedGoogle Scholar
  16. 16.
    Savona S, Nardi MA, Lennette ET, Karpatkin S. Thrombocytopenic purpura in narcotics addicts. Ann Intern Med 1985;102:737–741PubMedGoogle Scholar
  17. 17.
    Zauli G, Re MC, Davis B, Sen L, Visani G, Gugliotta L, Furlini G, La Placa M. Impaired in vitro growth of purified (CD34+) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals. Blood 1992;79:2680–2687PubMedGoogle Scholar
  18. 18.
    Kunzi MS, Groopman JE. Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood 1993;81:3336–3342PubMedGoogle Scholar
  19. 19.
    Klaassen RJL, Mulder JW, Vlekke ABJ, Schattenkerk JKME, Weigels HM, Lange JMA, von dem Borne AEGK. Autoantibodies against peripheral blood cells appear early in HIV infection and their prevalence increases with disease progression. Clin Exp Immunol 1990;81:11–17PubMedCrossRefGoogle Scholar
  20. 20.
    Sloand EM, young NS, Sato T, Kumar P, Kim S, Weichold FF, Maciejewski JP. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS 1997;11:1547–53PubMedCrossRefGoogle Scholar
  21. 21.
    Kotler DP, Dulpepper-Morgan JA, Tierney AR, Klein EB. Treatment of disseminated cytomegalovirus infection with 9-(1,3 dihydroxy-2-propoxymethyl) guanine: evidence of prolonged survival in patients with the acquired immunodeficiency syndrome. AIDS Res 1986;2:299–308PubMedCrossRefGoogle Scholar
  22. 22.
    Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987;83:201–207PubMedCrossRefGoogle Scholar
  23. 23.
    Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche cooperative Oral Ganciclovir Study Group. N Engl J Med 1996;334:1491–7PubMedCrossRefGoogle Scholar
  24. 24.
    Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologie effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929–940PubMedGoogle Scholar
  25. 25.
    Little BJ, Spivak JL, Quinn TC, Mann RB. Kaposi’s sarcoma with bone marrow involvement: occurrence in a patient with the acquired immunodeficiency syndrome. Am J Med Sci 1986;292:44–46PubMedCrossRefGoogle Scholar
  26. 26.
    Sparano JA, Wiernik PH, Hu X, et al: A pilot trial of infusional cyclophosphamide, doxorubicin and etonoside plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin’slymphoma. J Clin Oncol 1996; 14: 3026–3035PubMedGoogle Scholar
  27. 27.
    Kitano K, Abbound CN, Ryan DH, Qkuan SG, Baldwin GC, Golde DW. Macrophage-active colony stimulating factors enhanced human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood 1991;77:1699–1705PubMedGoogle Scholar
  28. 28.
    Steinberg FIN, Crempacker CS, Chatis PA. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol 1991;65:1765–1769PubMedGoogle Scholar
  29. 29.
    Stanley SK; Kessler SW; Justement JS; Schnittman SM, Greenhouse JJ, Brown CC, Musongela L, Musey K, Kapita B, Fauci AS. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992;149;689–97PubMedGoogle Scholar
  30. 30.
    Molina JM, Scadden DT, Sakaguchi M, Fuller B, Woon A, Groopman JE. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990;76:2476–2482PubMedGoogle Scholar
  31. 31.
    Neal TF, Holland HK, Baum CM, et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86:1749–1756PubMedGoogle Scholar
  32. 32.
    Weichold FF, Zella D, Dunn D, Sloand EM, Maciejewski JP, Young NS. Neither HIV-1 nor HIV-2 infect most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood 1998; 91: 907–915PubMedGoogle Scholar
  33. 33.
    Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, Loveless M, Bagby G, Nelson JA. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996;87:919–925PubMedGoogle Scholar
  34. 34.
    Rieckmann P, Poli G, Fox CH, Kehrl JH, Fauci AS. Recombinant gp 120specifically enhances tumor necrosis factor-alpha production and lg secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol 1991;147:2922–2927PubMedGoogle Scholar
  35. 35.
    Voth RA, Rossol S, Klein K, Hess G, Shutt KH, Schroeder HC, Meyer zum Buschenfelde KH, Mulleer WEG. Differential gene expression of interferon-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS. J Immunol 1990;144:970–975PubMedGoogle Scholar
  36. 36.
    Maciejeski JP, Weichold FF, Young NS. HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. J Immunol 1994;153:4303–4310Google Scholar
  37. 37.
    Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL. The HIV-1 gp 120 envelope proteins has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991;147:2892–2901PubMedGoogle Scholar
  38. 38.
    Lau AS, Williams BR. The role of interferon and tumor necrosis factor in the pathogenesis of AIDS. J Exp Pathol 1990;5:111–122PubMedGoogle Scholar
  39. 39.
    Odeh M. The role of tumor necrosis factor-alpha in acquired immunodeficiency syndrome. J Intern Med 1990;228:549–556PubMedCrossRefGoogle Scholar
  40. 40.
    Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995;165:538–546PubMedCrossRefGoogle Scholar
  41. 41.
    Rusten LS, Jacobsen FW, Lesslauer W, Loetscher R, Gentz R,Jacobsen SEW. Bifunctional effects of TNF-a on the growth of mature and primitive human hematopoietic progenitor cells. Blood 1994a;83:3152–3159PubMedGoogle Scholar
  42. 42.
    Schwartz GN, Kessler SW, Rothwell SW, Burrell LM, Reid TJ, Meltzer MS, Wright DG. Inhibitory effects of HIV-1-infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures. Exp Hematol 1994;22:1288–1296PubMedGoogle Scholar
  43. 43.
    Fuchs D, Reibnegger G, Werner ER, Vinazzer H, Wachter H. Low haemoglobin in haemophilia children is associated with chronic immune activation. Acta Haematol 1991;85:6265CrossRefGoogle Scholar
  44. 44.
    Kagi D, Vignaux F, Ledermenn B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science 265:528;1994PubMedCrossRefGoogle Scholar
  45. 45.
    Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br J Hematol 1995;91:245–252CrossRefGoogle Scholar
  46. 46.
    Sloand EM, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48–53PubMedCrossRefGoogle Scholar
  47. 47.
    Sloand EM, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48–53PubMedCrossRefGoogle Scholar
  48. 48.
    Busch MP, Lee TH, Heitman J Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992;80:2128–2135PubMedGoogle Scholar
  49. 49.
    Mudido PM, Georges D, Dorazio D, Yen-Lieberman B, Bae S, O’Brien WA, Spritzler J, Lederman MM: Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36:860--865PubMedCrossRefGoogle Scholar
  50. 50.
    Henry DH, Beall GN, Benson CA. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and Zidovudine therapy. Ann Intern Med 1992;117:739–748PubMedGoogle Scholar
  51. 51.
    Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989;320:974–980PubMedCrossRefGoogle Scholar
  52. 52.
    Ballem P. Segal GM, Stratton JR. Gersheimer T Adamson JW. Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33–40PubMedCrossRefGoogle Scholar
  53. 53.
    Ratner L. Human immunodeficiency virus-associated autoimmune thrombocytopenic purpura: a review. Am J Med 1989;86:194–8PubMedCrossRefGoogle Scholar
  54. 54.
    Pottage JC, Benson CA, Spears JB, Landay Al, Kessler HA. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine JAMA 1988;260:3045–8Google Scholar
  55. 55.
    Ellis ME, Neal KR, Leen CL, Newland AC. Alfa-2a recombinant interferon in HIV associated thrombocytopenia. Br Med J 1987;295:1519CrossRefGoogle Scholar
  56. 56.
    Bussel JB, Haimi JS Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin. Am J Hematol 1988;28:79–84PubMedCrossRefGoogle Scholar
  57. 57.
    Scaradavou A, Woo B, Woloski BM, Cuningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–700PubMedGoogle Scholar
  58. 58.
    Mintzer DM, Real FX, Jovino L, Krown SE. Treatment of Kaposi’s sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome.Ann Intern Med 1985;102:200–2PubMedGoogle Scholar
  59. 59.
    Brown SA, Majumdar G, Harrington C, Bedford M, Winter M, 0-Doherty MJ, Savidge GF. Effect of splenectomy on HIV-related thrombocytopenia and progression of HIV infection in patients with severe haemophilia. Blood Coagul Fibrinolysis 1994;5:393–397PubMedGoogle Scholar
  60. 60.
    Schneider PA, Abrams DI, Rayner AA, Hohn DC. Immunodeficiency-associated thrombocytopenic purpura (IDTP). Response to splenectomy. Arch Surg 1987;122:1175–8PubMedCrossRefGoogle Scholar
  61. 61.
    Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404–9PubMedCrossRefGoogle Scholar
  62. 62.
    Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin. Hematol. 1998; 35, 261–8Google Scholar
  63. 63.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996; 348, 1279–81PubMedCrossRefGoogle Scholar
  64. 64.
    Harker LA, Marzek UM, Novembre F, Sundell IB, Waller EK, Karpatkin S, McClure HM, Kelly AB, Stead RB. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood. 1998; 91, 4427–33PubMedGoogle Scholar
  65. 65.
    Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068–4071PubMedGoogle Scholar
  66. 66.
    Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368–77PubMedGoogle Scholar
  67. 67.
    Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607–14PubMedGoogle Scholar
  68. 68.
    Tumbarello M; Tacconelli E; Caponera S; Cauda R; Ortona L. The impact of bacteraemia on HIV infection. Nine years experience in a large Italian University hospital. J Infect 1995;31:12331CrossRefGoogle Scholar
  69. 69.
    Keiser P, Higgs E, Smith J. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus. Am J Med Sci 1996:312;118–22PubMedCrossRefGoogle Scholar
  70. 70.
    Mathews WC, Caperna J, Toerner JG, Barber RE, Morgenstern H. Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study. Am J Epidemiol. 1998;148;1175–83PubMedCrossRefGoogle Scholar
  71. 71.
    Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–60Google Scholar
  72. 72.
    Elbim C, Prevot MH, Bouscarat F, Franzini E, Chollet-Martin S, Hakim J, Gougerot-Pocidalo MA. Impairment of polymorphonuclear neutrophil function in HIV-infected patients. J Cardiovasc Pharmacol 1995; 25: Suppl 2: S66–70CrossRefGoogle Scholar
  73. 73.
    Flo RW, Naess A, Nilsen A, Harthug S, Solberg CO. A longitudinal study of phagocytefunction in HIV-infected patients. AIDS 1994;8:771–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA. Rubin M. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony stimulating factor. J Pediatr 1990; 117: 531–540.PubMedCrossRefGoogle Scholar
  75. 75.
    Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J. Clin Invest 1998; 102,663–70PubMedCrossRefGoogle Scholar
  76. 76.
    Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MA. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998; 12, 65–74PubMedCrossRefGoogle Scholar
  77. 77.
    Rossi G, Donisi A, Casari S, Re A, Stellini R, Cadeo G, Carosi G. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkins lymphoma (NHL). Haematologica. 1998; 83, 317–22PubMedGoogle Scholar
  78. 78.
    Hammer SM, Gillis JM, Pinkston P, Rose RM. Effect of zidovudine and granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus replication in alveolar macrophages. Blood 1990;75:1215–1219PubMedGoogle Scholar
  79. 79.
    Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudineinduced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood. 1997:78;3148–54Google Scholar
  80. 80.
    Hardy D, Spector S, Polsky B, Crumpacker C, van der Horst C, Holland G, Freeman W, Heinemann MI-1, Sharuk G, Klystra J. Combination of ganciclovir and granulocyte-macrophage colony - stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 1994:13; sup 2: S34–40CrossRefGoogle Scholar
  81. 81.
    Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracy J, Mills J, Volberding PA. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol. 1997;9:929–40Google Scholar
  82. 82.
    Barbaro G, Di Lorenzo G, Grisorio B, Soldini M, Barbarini G. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study. AIDS 1997; 11, 1453–61PubMedCrossRefGoogle Scholar
  83. 83.
    Scadden DT, Wang A, Zsebo KM, Groopman JE. In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS 1994;8:193–196PubMedCrossRefGoogle Scholar
  84. 84.
    Von Roenn JI-1, Gordon LI, Grace WR, Lee S. Recombinant IL-3 in HIV seropositive patients with cytopenias: effective long term therapy. Proc Am Soc Clin Oncol 1996; 15: 305 (abstr 851)Google Scholar
  85. 85.
    Ashman LK. The biology of stem cell factor and its receptor C-kit. In J Biochem Cell 1999; 31: 1037–1051CrossRefGoogle Scholar
  86. 86.
    Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169–76PubMedCrossRefGoogle Scholar
  87. 87.
    Rook AH, Masur H, Lane HC, Frederick W, Kasahara T, Macher AM, Djeu JY, Manischewitz JF, Jackson L, Fauci AS, Quinnan GV Jr. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983:72;398–403PubMedCrossRefGoogle Scholar
  88. 88.
    Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996:335;1350–6PubMedCrossRefGoogle Scholar
  89. 89.
    Wood R, Montoya JG, Kundu SK, Schwartz Dh, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993:167:519–25PubMedCrossRefGoogle Scholar
  90. 90.
    Davey RT Jr, Chain DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999:179:849–58PubMedCrossRefGoogle Scholar
  91. 91.
    Chung TW, Engel D, Mizel SB, Hallahan CW, Fischette M, Park S, Davey RT Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Brrey MM, Corey L, Lane HC, Fauci, AS. Effect of interleukin-2 on the pool of latently infected, resting CDE+ T cells in HIV-1-inected patients receiving highly active anti-retroviral therapy. Nat Med 1999:5:651–5CrossRefGoogle Scholar
  92. 92.
    Murphy PM, Lane HC, Gallin JI, Fauci ASA. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med 1988:108;36–41PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Elaine Sloand
    • 1
  1. 1.National Institute of HealthUSA

Personalised recommendations